Skip to main content

Table 2 Patients characteristics and outcomes

From: A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome

Case

Dose of peptide (mg)

Age

Sex

PS

Site of desease

Previous treatment*

IFN γ response to each peptide

Number of vaccination

Period of vaccinations (days)

Toxicity

Response

Prognosis (days)

Treatments after vaccination

R

T

K

R1

R2

Injection site reaction

General

PFS

OS

Pre vaccinations

Within 3 courses of vaccinations

Within 6 courses of vaccinations

1

0.5

56

M

0

LN

IRI, OX, FU

++

85

2150

2

None

CR

2150

2150

A

None

+

++

+

++

+

++

2

0.5

72

F

1

Lung, bone

IRI, OX, FU

16

120

1

None

PD

60

191

D

None

+

+

+

+

+

3

0.5

75

M

1

Liver, lung

IRI, OX, FU

++

27

364

1

None

SD

158

406

D

OX, FU, BEV

++

+

++

+

+

4

1

59

F

2

Dissemi.

IRI, OX, FU

8

49

1

None

PD

36

80

D

None

++

++

+

+

5

1

68

M

0

Lung

IRI, OX, FU

25

329

2

None

PD

68

1009

D

OX, FU, IRI, BEV, CETU

++

+

++

+

++

++

+

++

+

++

6

1

69

M

2

Lung, LN

IRI, OX, FU

+

13

84

2

None

PD

62

110

D

None

++

++

8

3

85

F

1

Dissemi.

FU

11

70

2

None

PD

103

461

D

IRI, FU

+

+

9

3

59

M

0

Lung

IRI, OX, FU

+

45

777

2

None

SD

221

885

D

None

++

++

++

++

++

++

++

++

10

3

49

F

0

Liver, lung

IRI, FU

++

39

777

2

Fever <38.0°C

PD

69

834

D

OX, FU, IRI, BEV

+++

++

++

+

+++

++

++

+

11

3

46

F

0

Lung

none

13

64

2

Erythena (G1)

SD

117

1029

D

OX, FU, IRI, BEV

+

++

+++

++

+

++

+++

++

12

3

71

M

0

Local

OX, FU

63

959

2

None

SD

120

1059

D

IRI, FU, OX, BEV

+

++

++

+

+

++

++

+

+

13

3

71

M

2

Liver, lung, bone

IRI, OX, FU, RAD

8

49

1

None

PD

57

133

D

None

++

++

++

++

14

3 (mix)

65

F

2

Dissemi.

IRI, OX, FU

8

49

1

None

PD

50

342

D

None

+

+

++

+

++

+

+

++

+

++

15

3 (mix)

71

M

2

Liver, lung

IRI, OX, FU

8

49

1

None

PD

36

102

D

None

+

+++

++

+

+++

++

16

3 (mix)

57

M

1

Local

none

++

38

749

2

None

SD

771

1161

D

None

+

+++

+++

+

++

+++

+++

17

3 (mix)

65

M

1

Dissemi.

OX, FU

+

+++

16

126

2

None

PD

69

145

D

None

+

+

+

+++

+

+

+

+

+++

+

18

3 (mix)

55

F

0

Local

IRI, FU

+

+

8

49

2

None

SD

56

56

A

Curative resection

+

+

19

3 (mix)

58

F

2

Liver, Dissemi.

OX, FU, BEV

++

+

+

8

49

1

None

PD

37

52

D

None

++

+

++

+

++

+

++

+

  1. PS: Eastern Cooperative Oncology Group performance status, LN: lymph nodes, Dessemi: peritoneal dissemination, PFS: progression free survival, OS: over all survival.
  2. IRI: irinotican, OX: oxaliplatin, FU: fluoropyrimidine, RAD: radiation, BEV: bevacizumab, CETU: cetuximab, R: RNF43, T: TOMM34, K: KOC1, R1: VEGFR1, R2: VEGFR2, D: daed, A: alive.
  3. CR:complete response, PR: partial response, SD: stable desease, PD: progression desease, *: operation was performed for all patients for the resection of primary lesions.